Alvotech Earnings Jump Nearly 600% Year Over Year
Alvotech’s revenues for the first 6 months of 2023 reached $22.7 million, a nearly 600% year-over-year increase.
The Top 5 Biosimilar Articles for the Week of August 28
Here are the top 5 biosimilar articles for the week of August 28, 2023.
Biosimilars Business Roundup: August 2023
After a busy July, August brought hope for the biosimilars industry’s future, with the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and several analyses about the health of the market.
TNFi Switching Is Safe, Effective for Rheumatoid Arthritis, Study Suggests
Single switching between approved biologics and biosimilars of tumor necrosis factor inhibitors (TNFis) were found to be safe and effective for rheumatoid arthritis.
Stelara and Enbrel Chosen for IRA Price Negotiation
Stelara (ustekinumab) and Enbrel (etanercept), 2 originator medications that will face biosimilar competition within the next decade, were among the 10 preliminary drugs chosen for Medicare price negotiation under the Inflation Reduction Act (IRA).
Pharmacy Can Help Drive Adoption of Rheumatoid Arthritis Biosimilars
Pharmacists will have the opportunity to use their knowledge of biosimilars to reinforce their benefits, safety, and efficacy.
Cardinal Health's Dr Fran Gregory Reacts to First MS Biosimilar Approval
Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, shares her reaction to the FDA approval of Tyruko (natalizumab-sztn), the first biosimilar approved to treat multiple sclerosis (MS).
Meta-Analysis Confirms Clinical Equivalence Between RA Biosimilars, Originators
A meta-analysis and systematic review of data on over 10,000 patients with rheumatoid arthritis (RA) found that etanercept, adalimumab, and infliximab biosimilars were clinically equivalent to their reference products.
FDA Approves First MS Biosimilar
The FDA approved its first biosimilar indicated for multiple sclerosis (MS), Sandoz’ Tyruko (natalizumab-sztn), a biosimilar referencing Tysabi (natalizumab).
The Top 5 Biosimilar Articles for the Week of August 21
Here are the top 5 biosimilar articles for the week of August 21, 2023.
Biosimilar Teriparatide Improves BMD for Patients With Osteoporosis, Study Finds
Biosimilar teriparatide improves bone mineral density (BMD) when patients with osteoporosis are treated for a year or more.
Cardinal Health Exec: How Adalimumab Biosimilars Can Reshape the US Health Care Industry
Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, published her opinions on the future of biosimilars in the United States, foreshadowing immense growth and a transformation of the US health care industry thanks to biosimilars.
Contributor: What’s Behind the Slow Uptake of Biosimilars in the US?
Dan Danielson, RPh, MS, senior director, market access solutions, at PrecisionValue, a market access marketing firm, explains the remaining issues at play slowing down biosimilar uptake in the United States.
BioRationality: A Calculated View on the Future of Biosimilars
Sarfaraz K. Niazi, PhD, recapped his answers to a recent interview where he discussed his predictions on the future of the biosimilar industry in the United States.
How Streamlining Development Can Save the US Biosimilar Industry
On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, expanded on ways to make biosimilar development faster and cheaper without compromising on safety and efficacy and how these practices can ensure a sustainable market for the future.
The Top 5 Biosimilar Articles for the Week of August 14
Here are the top 5 biosimilar articles for the week of August 14, 2023.
Biocon Biosimilar Quarterly Sales Up 106%
In Biocon’s latest quarterly earnings report, the company revealed that sales for its biosimilars portfolio rose 106% compared with the same time frame the year prior.
STADA Earnings Project Record Breaking Profits for 2023
In STADA Arzneimittel’s first half of 2023 earnings report, the company disclosed double-digit growth, suggesting that it could see profits hit an all-time high by the end of the year.
Study: Ranibizumab Biosimilar Is the Most Cost-Effective Option for nAMD
Ranibizumab biosimilar was found to be the most cost-effective for neovascular age-related macular degeneration (nAMD), according to a recent Japanese study.
Contributor: The Promise of RA Biosimilars Could Be Realized, but Greater Adoption Rates Are Needed
Robert Zutaut, RPh, a clinical specialist from McKesson Provider Solutions, quantifies the major barriers to adoption for biosimilars used to treat rheumatoid arthritis (RA) and some major considerations for health systems looking to address them.
Oncological Biosimilars Shown to Be as Safe as Their Reference Products
Study finds patients with cancer feel reassured that biosimilars provide a safe, adequate, and cost-effective alternative to the pricier reference drug.
Research Confirms Long-Term Stability of Adalimumab Biosimilar Candidate TUR01
A study on the stability of the adalimumab biosimilar candidate TUR01, a tumor necrosis factor-α inhibitor, found long-term stability of the drug substance and drug product were maintained under different temperatures.
The Top 5 Biosimilar Articles for the Week of August 7
Here are the top 5 biosimilar articles for the week of August 7, 2023.
Spanish Psoriasis Working Group Revises Guidelines for Biosimilars in Psoriasis
The Spanish Psoriasis Working Group updated its position on the use of biosimilar medicines in patients with moderate to severe psoriasis, including its views on biosimilars as first-line treatment and nonmedical switching.
Authors Suggest Major Policy Shifts to Boost Biosimilar Development, Accessibility
Streamlining biosimilar development would permit biosimilar development of more and a wider variety of biological drugs, fast-tracking biosimilar development without impacting patient safety or effectiveness, according to an opinion piece.
Sintilimab Plus Bevacizumab Biosimilar vs Avastin Is Cost-Effective in HCC
A Chinese study proved that combination therapy with sintilimab and a bevacizumab biosimilar was cost-effective enough in patients with hepatocellular carcinoma (HCC) to warrant use of the biosimilar over the reference product (Avastin) without compromising safety or efficacy.
BioRationality: The Adulthood of Biosimilars—Global Status and Future of Biosimilars
Sarfaraz K. Niazi, PhD, gives an overview of the global biosimilar landscape, noting why some countries have biosimilars, including follow-on biologics and unbranded biologics, for certain products and why others do not.
Biosimilars Immunology Roundup for July 2023—Podcast Edition
On this episode, we’re giving a rundown of some of the biggest stories in the immunology space regarding biosimilars, like the launch of 7 adalimumab biosimilars, the release of multiple market trend reports, and clinical trial results on traditionally bypassed disease states.
Despite Global Increase in Amjevita Sales, US Sales Dropped 63%
Despite global sales for Amjevita (adalimumab-atto) growing by 29% year-over-year and the agent being the first adalimumab biosimilar on the US market, sales in the United States dropped 63% from the first quarter to the second quarter of 2023.
The Top 5 Biosimilar Articles for the Week of July 31
Here are the top 5 biosimilar articles for the week of July 31, 2023.
2 Clarke Drive Cranbury, NJ 08512